Device Trial Radar · NCT06992089
SHort Of Pace - Heart Failure (SHOP-HF)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jun 17, 2025
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Fundación para la Investigación del Hospital Clínico de ValenciaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 28, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed as a multicenter, prospective, controlled, randomized, two-arms, cross-over, two parallel cohorts, efficacy Clinical research with CE-marked medical device . The crossover trial will be performed in a blind fashion, so each participant will be evaluated during both blinded pacing-on and pacing-off phases, each of which will last 3 months. The population includes patients with the diagnosis of stable HFpEF according to criteria of the European Society of Cardiology and New York Heart Association (NYHA) functional class II-III/IV, left ventricular hypertrophy with small ventricular volume, sinus rhythm with low basal heart rate and chronotropic incompetence (CI). All patients will undergo pacemaker implantation, and computer-generated randomization sequence previously designed will be used to allocate participants (in a 1:1 ratio) to receive: (a) programming of the pacemaker with pacing On followed by pacing Off in two periods of 3 months; or (b) programming of the pacemaker with pacing Off followed by pacing On in two periods of 3 months. The study will be conducted in three centers in Spain. Discounting the time due to staggered entry, the total duration of a patient's follow-up will be 7 months.
Conditions
- Heart Failure With Preserved Ejection Fraction
Interventions
Dual-chamber cardiac pacemaker (Proponent MRI L211/L231 or Accolade MRI L311/L331, Boston Scientific), single-chamber cardiac pacemaker (Essentio MRI L110 or Accolade MRI L310, Boston Scientific)Device
Dual-chamber cardiac pacemaker (Proponent MRI L211, Proponent MRI L231, Accolade MRI L311 or Accolade MRI L331, Boston Scientific), with rate-adaptive pacing of the right atrium. There will be an associated right atrial lead (INGEVITY™+ MRI pacing lead) and right ventricular lead (INGEVITY™+ MRI pacing lead). Single-chamber cardiac pacemaker (Essentio MRI L110 or Accolade MRI L310, Boston Scientific), with rate-adaptive pacing of the ventricles. There will be an associated right ventricular lead (INGEVITY™+ MRI pacing lead).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak oxygen uptakeTime frame: 3 months after the pacemarker stimulation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Clínico de la Comunidad Valenciana
Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.